|
World Multiple Myeloma Drug Treatment Market 2011-2021
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
Our report gives you the following advantages:That mix of quantitative and qualitative market analysis sets our report apart. Our analysis helps you to stay ahead in commercial knowledge for myeloma treatments. Order our report now to gain industry and market information you need Our report can benefit everybody interested in the commercial potential of multiple myeloma treatments and related R&D. We give predictions and answers you need. Don't miss out - please order our report now. Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6 150 seiten | |||||||||||
| Inhalt der Studie: |
What are the prospects for the multiple myeloma treatment market from 2011? Our new report shows you its revenue potential from 2011 to 2021. We predict and explain the commercial opportunities in tha.....
What are the prospects for the multiple myeloma treatment market from 2011? Our new report shows you its revenue potential from 2011 to 2021. We predict and explain the commercial opportunities in that industry and market. Our report gives you revenue forecasts to 2021 for myeloma drugs. You will discover market predictions at total world, product and national levels. We aim to save you time and aid your decisions through our research, analysis and discussions. You will see how drugs like Revlimid, Velcade, Thalomid and Carfilzomib can perform to 2021. We discuss J&J, Takeda, Celgene, Novartis, Onyx and many other companies. There are good opportunities for companies seeking to enter the myeloma treatment market. Our study reviews R&D activities. We discuss MAbs, histone deacetylase inhibitors, heat shock protein modulators, apoptosis inducers and signal transduction blockers/protein kinase inhibitors. We also cover immunomodulators, interferons and proteasome inhibitors. We help you to assess the multiple myeloma treatment industry and market's strengths, weaknesses, trends and revenue opportunities to 2021. You will see what its future holds. Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now. Industry and market analysis to help your work - so you won't be left behind Our report gives you revenue forecasts, growth rates and market shares. We also provide a SWOT/STEP review and coverage of the extensive R&D pipeline. We include 68 tables and charts (shown in the accompanying lists). Report Highlights Companies Listed Abbott Abgenix Abraxis AB Science Acceleron Acetylon Adeona AERES Biomedical Aeterna Zetaris Alexion ALZA Amgen Amo AmpliMed Anthrogenesis Apexigen Arizona University Array BioPharma Astellas Astex Therapeutics AstraZeneca Attenuon AVEO Bayer Bayer Schering Biogen Idec BioInvent Biotest BioWa Boehringer Ingelheim Bristol-Myers Squibb (BMS) British Biotech BTG Canadian National Research Council Celanese Cell Therapeutics Cephalon Celgene Corporation Centocor Ortho Biotech Cetus Corporation Chiron Choongwae Chugai Cleveland Clinic Columbia University Compugen Constellation Pharmaceuticals Cougar Biotechnology Crinos CTI Technologies CyDex Cylene Cytogen CytRx Daiichi Sankyo Dana Farber Cancer Institute Elan Elara Eli Lilly EntreMed Epizyme European Medicines Agency (EMA/EMEA) European Molecular Biology Laboratory EUSA Pharma Exelixis Facet Biotech Food and Drug Administration (US FDA) Galapagos Genentech Genmab Genta Genzyme Geron GlaxoSmithKline (GSK) Gloucester Pharmaceuticals GlycoGenesys GlycoMimetics Greenwich Therapeutics GTC Biotherapeutics Handok Harvard University Human Genome Sciences ILEX Oncology Immune System Therapeutics ImmunoGen Immunomedics Incyte Innate Pharma Intellikine International Myeloma Working Group Italfarmaco Janssen Janssen-Cilag Johnson & Johnson Kaken Karyopharm Therapeutics Keryx Pharmaceuticals Keyaku Zentaris Kosan Biosciences Kyowa Hakko Kirin Leuchemix Ligand Lipomed Mannkind Marlborough Research and Development MD Anderson Cancer Center MedImmune Merck & Co. Merck Serono Micromet Millennium Pharmaceuticals MorphoSys Multiple Myeloma Research Consortium (MMRC) Multiple Myeloma Research Foundation Natco Pharma National Cancer Institute (US) National Institute for Health and Clinical Excellence (UK NICE) Nereus Nerviano Medical Sciences Nippon Shinyaku Novartis Novo Nordisk Ohio State University Onconova Ono Onyx Pharmaceuticals Ortho Biotech Otsuka PDL BioPharma Pfizer Pharmacia Corporation Pharmacopeia PharmaMar Pharmion Pierre Fabre Pipex Piramal Life Sciences PIramed PolaRx Biopharmaceuticals Progenra Prospect Therapeutics Protein Design Proteolix Rigel R&R Roche Rockefeller University S*BIO Sanofi-Aventis Schering-Plough Scripps Institution of Oceanography Seattle Genetics Semafore Senesco Shire Sigma-Tau Signal Pharmaceuticals Sirton Sloan Kettering Institute Sunesis Takeda Teva Pharmaceutical Industries Texas A&M University TMRC Toko Tragara University of Basle Pharmacenter University of Cambridge University of Illinois University of Kentucky College of Pharmacy University of Michigan University of San Diego US National Comprehensive Cancer Network Vernalis VioQuest Wayne State University World Health Organisation (WHO) Wyeth (now part of Pfizer) Xencor XOMA XTL Biopharmaceuticals YM Biosciences Zelos Zeltia Zeria Ziopharm [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 1.1 Multiple Myeloma Market Review 1.2 Contents of this Report 1.3 Research and Analysis Methods 2. Introduction to Multiple Myeloma 2.1 What is Multiple Myeloma? 2.1.1 Plasma Cells in the Healthy Body and in Multiple Myeloma Patients 2.2 Symptoms of Multiple Myeloma 2.3 Diagnosing Multiple Myeloma: M Proteins 2.3.1 Other Diagnostic Tests 2.4 Multiple Myeloma Represents 10-15% of all Blood Cancers 2.5 Demographic Risk Variation in Multiple Myeloma 2.6 Other Environmental and Genetic Risk Factors for Multiple Myeloma 2.7 Stages of Multiple Myeloma 2.7.1 Monoclonal Gammopathy of Undetermined Significance 2.7.2 Smouldering Multiple Myeloma 2.7.3 The Durie-Salmon Staging System and the International Staging System 2.8 Development of Multiple Myeloma Treatment Options 2.8.1 Classification of Treatment Options 2.8.2 Traditional Antineoplastics 2.8.3 Novel Antineoplastics 2.8.4 Hormone Therapies 2.8.5 Immunotherapies 2.8.6 Present and Future Options for Treating Multiple Myeloma: Summary 3. The Global Multiple Myeloma Market 2011-2021 3.1 The Global Market Will Show Impressive Growth Through to 2021 3.2 Around 100 Products are in Clinical Trials for Multiple Myeloma 3.3 New Classes of Drug Will Reach the Market during the Forecast Period 3.4 Several Major Pharmaceutical Companies Will Enter the Multiple Myeloma Market 3.5 The Global Market Will Continue to Grow 4. Multiple Myeloma Market in 2011 4.1 Existing Products 4.2 Revlimid (Celgene Corporation) 4.2.1 Sales Forecast for Revlimid 2011-2021 4.2.2 Revlimid is Patent-Protected until 2026 in the US 4.2.3 Revlimid as a Possible Maintenance Therapy 4.3 Velcade (Johnson & Johnson/Takeda) 4.3.1 Sales Forecast for Velcade, 2011-2021 4.3.2 Velcade as First-Line Therapy 4.4 Thalomid (Celgene Corporation) 4.4.1 Sales Forecast for Thalomid 2011-2021 4.4.2 Generic Thalidomide: Teva Leads the Field 4.5 Other Products 4.5.1 Doxil (Johnson & Johnson) 4.6 Treatment Plans for Multiple Myeloma: a Key Market Feature 4.6.1 Stem Cell Transplantation: an Important Option for Standard-Risk Patients 4.7 Stages of Therapy 4.8 Induction Therapy 4.8.1 HCT Following Induction Therapy 4.8.2 Allogeneic Transplantation: a Possible Cure? 4.8.3 Pre-HCT Regimens with Novel Agents 4.8.4 Side-Effects of Chemotherapeutic Treatment 4.8.5 Radiotherapy: Key Treatment for Plasmacytoma 4.8.6 The 'Plateau': After Induction Therapy 4.9 Consolidation Therapy 4.9.1 Consolidation Therapy as an Aspect of 'Total Therapy' 4.10 Maintenance Therapy 4.11 Salvage Therapy 5. The Next Generation of Multiple Myeloma Treatments 5.1 Carfilzomib (Onyx Pharmaceuticals) 5.1.1 Carfilzomib: a Potential Blockbuster 5.1.2 Sales Forecast for Carfilzomib 2011-2021 5.2 Actimid (Celgene Corporation) 5.2.1 Actimid: a Successor to Revlimid's Market Dominance? 5.2.2 Sales Forecast for Actimid 2011-2021 5.3 Panobinostat (Novartis) 5.3.1 Panobinostat: Leading the HDAC Inhibitors to Market 5.3.2 Sales Forecast for Panobinostat 2011-2021 5.4 Perifosine (Keryx Pharmaceuticals/Aeterna Zetaris) 5.4.1 Perifosine: First of Many Kinase Inhibitors? 5.4.2 Sales Forecast for Perifosine 2011-2021 5.5 Aplidin (Pfizer/PharmaMar) 5.5.1 Aplidin: an Underrated Phase III Candidate? 5.5.2 Sales Forecast for Aplidin 2011-2021 5.6 Elotuzumab (Abbott/Bristol-Myers Squibb) 5.6.1 Elotuzumab: Most Significant MAb in Multiple Myeloma Pipeline? 5.6.2 Sales Forecast for Elotuzumab 2011-2021 5.7 Siltuximab (Johnson & Johnson) 5.7.1 Siltuximab: First MAb to the Myeloma Market? 5.7.2 Sales Forecast for Siltuximab 2011-2021 5.8 Other Products Reaching the Market 2011-2021 5.8.1 Bonoteo (Ono/Astellas) 5.8.2 Limited Potential for Bonoteo 6. The Pipeline I: Small-Molecule Products 6.1 Proteasome Inhibitors: The Next Generation 6.1.1 CEP 18770 (Cephalon) 6.1.2 Marizomib (Nereus) 6.1.3 MLN 9708 (Takeda) 6.1.4 CEP 28331 (Cephalon) 6.2 Immunomodulators: The Past or the Future for Myeloma Treatment? 6.2.1 Afinitor (Novartis) 6.2.2 E-Selectin Antagonists (GlycoMimetics) 6.3 Histone Deacetylase Inhibitors: an Important New Sector 6.3.1 Isotdax (Celgene Corporation) 6.3.2 Zolinza (Merck & Co.) 6.3.3 AR 42 (Arno) 6.3.4 Givinostat (Italfarmaco) 6.3.5 HDAC6 Inhibitors (Acetylon) 6.4 Kinase Inhibitors/Signal Transduction Blockers: The Largest Pipeline Sector 6.4.1 Votrient (GlaxoSmithKline) 6.4.2 Lenocta (VioQuest) 6.4.3 Ruxolitnib (Novartis) 6.4.4 Lestaurtnib (Cephalon) 6.4.5 Masitnib (AB Science) 6.4.6 AT 9283 (Astex Therapeutics) 6.4.7 Dovitnib (Novartis) 6.4.8 P276 (Piramal Life Sciences) 6.4.9 PD 332991 (Pfizer) 6.4.10 ENMD 2076 (EntreMed) 6.4.11 AT 7519 (Astex Therapeutics) 6.4.12 MLN 8237 (Takeda) 6.4.13 Estybon (Oncova) 6.4.14 CX 4945 (Cylene) 6.4.15 GDC 0941 (Roche) 6.4.16 INK 128 (Intellikine) 6.4.17 SF 1126 (Semafore) 6.4.18 SNS 032 (Sunesis/'Bristol-Myers Squibb) 6.4.19 Sprycel (Otsuka/Bristol-Myers Squibb) 6.4.20 TG 02 (Tragara/S*BIO) 6.4.21 R763 (Rigel) 6.5 Heat Shock Protein Modulators: Life after Tanespimycin 6.5.1 AUY 922 (Novartis) 6.5.2 KW 2478 (Kyowa Hakko Kirin) 6.5.3 NVP BEP800 (Novartis) 6.6 Apoptosis Inducers: Four Products at Phase II 6.6.1 GCS 100 (Prospect Therapeutics) 6.6.2 Amplimexon (AmpliMed) 6.6.3 Trisenox (Nippon Shinyaku) 6.6.4 Noscapine (Cougar Biotechnology) 6.6.5 BMS 833923 (Bristol-Myers Squibb) 6.6.6 SNS 01-T (Senesco) 6.7 Other Products 6.7.1 Other Products in Phase II 6.7.2 Amnolake (CytRx) 6.7.3 Coprexa TM (Attenuon) 6.7.4 Brostallacin (Cell Therapeutics) 6.7.5 CYT 997 (YM Biosciences) 6.7.6 ARRY 520 (Array Biopharma) 6.7.7 Zinapar (Ziopharm) 6.7.8 Other Products in Phase I 6.7.9 Quadramet (EUSA Pharma) 6.7.10 LC1 (Leuchemix) 6.7.11 MLN 4924 (Takeda) 6.7.12 OPB 31121 (Otsuka) 6.7.13 Zalypsis (PharmaMar) 6.7.14 Other Products in Preclinical Studies 6.7.15 INNO 206 (CytRx) 6.7.16 Ostabolin-C (Zelos) 6.7.17 IRE1-alfa Inhibitor (Mannkind) 6.7.18 HIF Signalling Inhibitors (Elara) 6.7.19 PS 031291 (Ligand) 6.7.20 SST 001 (Sigma-Tau) 6.7.21 CGEN 928 (Compugen) 6.7.22 USP7 Inhibitors (Progenra) 6.8 High-Profile Development Failures 6.8.1 Time Runs Out for Leading Heat Shock Protein Modulator Candidate: Tanespimycin (Bristol-Myers Squibb) 6.8.2 Fall of the 'Anti-Ageing Drug': SRT501 (GlaxoSmithKline) 7. The Pipeline II: Biological Products 7.1 Monoclonal Antibodies: High Hopes in Multiple Myeloma Treatment 7.1.1 BHQ 880 (Novartis/MorphoSys) 7.1.2 Dacetuzumab (Seattle Genetics) 7.1.3 IPH 2101 (Novo Nordisk/Innate Pharma) 7.1.4 Milatuzumab (Immunomedics) 7.1.5 Samalizumab (Alexion) 7.1.6 Mapatumumab (Takeda) 7.1.7 Avastin (Roche) 7.1.8 Tysabri (Biogen Idec) 7.1.9 Daratumumab (Genmab) 7.1.10 Lucatumumab (Novartis/XOMA) 7.1.11 BI 505 (BioInvent) 7.1.12 BIW 8962 (BioWa) 7.1.13 MDX 1097 (Immune System Therapeutics) 7.1.14 Dalotuzumab (Pierre Fabre/Merck & Co) 7.1.15 AV 299 (Aveo) 7.1.16 Lorvotuzumab Mertansine (Immunogen) 7.1.17 LY 2127399 (Eli Lilly) 7.1.18 Campath (Genzyme) 7.1.19 MAb, CD-138-DM4 (Biotest) 7.1.20 APX 005 (Apexigen) 7.1.21 APX 007 (Apexigen) 7.1.22 MOR 202 (MorphoSys) 7.1.23 XmAb 5592 (Xencor) 7.1.24 BiTE MAb (Micromet/Boehringer Ingelheim) 7.2 Biological Products Other than Monoclonal Antibodies 7.2.1 PegIntron (Merck & Co) 7.2.2 ACE-011 (Celgene Corporation) 7.2.3 Imtelstat (Geron) 7.2.4 Dasovas (Sigma-Tau) 7.2.5 Recombinant Human Erythropoietin (XTL Biopharmaceuticals) 7.2.6 Genasense (Genta) 7.2.7 Future Epigenetics-Based Treatments 8. Leading Companies in the Multiple Myeloma Market 8.1 Celgene Corporation: Market Leaders 8.1.1 Can Celgene Maintain its Market Dominance? 8.2 Johnson & Johnson: First Proteasome Inhibitor and First MAb in the Market? 8.3 Novartis: The Biggest Multiple Myeloma Pipeline 8.3.1 Novartis' Multiple Myeloma Growth Strategy 8.4 Bristol-Myers Squibb: Multiple Pipeline Candidates 8.5 Onyx Pharmaceuticals: Lead Product Carfilzomib on Target 8.6 Cephalon: Pioneering Oral Proteasome Inhibitors 8.7 Keryx Biopharmaceuticals/Aeterna Zetaris: Small Companies to Watch 8.8 Merck & Co: Increasing Oncology Investment 8.9 Takeda: Strong Pipeline to Replace Velcade Revenues 8.10 Pfizer: Pharma Giant has Three Pipeline Candidates 9. Leading Countries in the Multiple Myeloma Market 9.1 The US Will Continue to Dominate the Multiple Myeloma Market in the 2011-2021 Period 9.2 Japan: 2010 Revlimid Approval to Drive Market Growth 9.3 The EU Top Five: Markets Outperforming the US 9.4 The BRIC Nations: Projected CAGR of Almost 25% for 2011-2021 9.4.1 Brazil: Government Investment to Fuel Growth 9.4.2 Russia: High Cancer Prevalence and Rapid Market Growth 9.4.3 India: The Fastest-Growing Major Market? 9.4.4 China: Pursuing Domestic Oncology R&D 10. Qualitative Analysis of the Multiple Myeloma Market 10.1 Strengths 10.1.1 Multiple Myeloma has Proven Commercial Potential 10.1.2 There are Extra Incentives to Enter the Myeloma Treatments Market 10.2 Weaknesses 10.2.1 The Multiple Myeloma Market is Heavily Dependent on a Few Products in 2011 10.2.2 The New Agents have Still to Prove Themselves Clinically and Commercially 10.3 Opportunities 10.3.1 Cancer Treatment is a Leading Business Area in the Pharmaceutical Industry 10.3.2 Increased Understanding of Genetics Boosts the Opportunities in Cancer Treatment 10.4 Threats 10.4.1 Healthcare Spending Restraints Threaten Cancer Drug Revenues 10.4.2 Other Factors May Threaten Revenues 11. Conclusions 11.1 Multiple Myeloma Treatment is a Thriving Market: It Will Continue to Expand from 2011 to 2021, with Many Opportunities for Companies 11.2 The R&D Pipeline for Multiple Myeloma Treatment is Large and Diverse 11.3 Biological Drugs Will Transform this Market 11.4 The Industry and Market have Commercial Challenges to Overcome 11.5 Concluding Remarks [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 3.1 Multiple Myeloma Global Market Forecast ($m, AGR, CAGR %), 2009-2021 Table 3.2 Top Ten Products in the Market ($m, AGR %, CAGR %), 2009-2021 Table 3.3 Top Companies in the Market ($m, % Shares), 2009 Table 3.4 Multiple Myeloma Pipeline Candidates: Leading Companies, 2011 Table 4.1 Revlimid Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 4.2 Velcade Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 4.3 Thalomid Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 5.1 Carfilzomib Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 5.2 Actimid Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 5.3 Panobinostat Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 5.4 Perifosine Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 5.5 Aplidin Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 5.6 Elotuzumab Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 5.7 Siltuximab Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 6.1 Multiple Myeloma R&D Pipeline: Small-Molecule Products, 2011 Table 6.2 Proteasome Inhibitor Pipeline, 2011 Table 6.3 Immunomodulator Pipeline, 2011 Table 6.4 Histone Deacetylase Inhibitor Pipeline, 2011 Table 6.5 Kinase Inhibitor/Signal Transduction Blocker Pipeline, 2011 Table 6.6 Heat Shock Protein Modulators Pipeline, 2011 Table 6.7 Apoptosis Inducers Pipeline, 2011 Table 6.8 Other Products Pipeline - Phase II, 2011 Table 6.9 Other Products Pipeline - Phase I, 2011 Table 6.10 Other Products Pipeline - Preclinical, 2011 Table 7.1 Pipeline Monoclonal Antibodies for Multiple Myeloma, 2011 Table 8.1 Celgene Corporation's Key Multiple Myeloma Products, 2011 Table 8.2 Johnson & Johnson's Key Multiple Myeloma Products, 2011 Table 8.3 Novartis' Key Multiple Myeloma Products, 2011 Table 8.4 Bristol-Myers Squibb's Key Multiple Myeloma Products, 2011 Table 8.5 Onyx Pharmaceuticals' Key Multiple Myeloma Products, 2011 Table 8.6 Cephalon's Key Multiple Myeloma Products, 2011 Table 8.7 Aeterna Zetaris/Keryx Biopharmaceuticals' Multiple Myeloma Product, 2011 Table 8.8 Merck & Co's Key Multiple Myeloma Products, 2011 Table 8.9 Takeda's Key Multiple Myeloma Products, 2011 Table 8.10 Pfizer's Key Multiple Myeloma Products, 2011 Table 9.1 Leading National Market Forecasts ($m, AGR %), 2009-2021 Table 9.2 US: Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 9.3 Japan: Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 9.4 EU Top 5 Market Forecasts ($m, AGR %, CAGR %), 2009-2021 Table 9.5 Brazil: Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 9.6 Russia: Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 9.7 India: Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 9.8 China: Market Forecast ($m, AGR %, CAGR %), 2009-2021 Table 10.1 Strengths and Weaknesses of the Market, 2011-2021 Table 10.2 Opportunities and Threats in the Market, 2011-2021 Figure 3.1 Multiple Myeloma Global Market Forecast ($m), 2009-2021 Figure 3.2 Top Ten Products Market Forecast ($m), 2009-2021 Figure 3.3 Top Mechanisms of Action ($m), 2009 Figure 3.4 Top Mechanisms of Action ($m), 2021 Figure 3.5 Top Companies in the Market ($m, % shares), 2009 Figure 3.6 Regional Distribution of Multiple Myeloma/Lymphoma Deaths, 2008 Figure 4.1 Revlimid Market Forecast ($m), 2009-2021 Figure 4.2 Velcade Market Forecast ($m), 2009-2021 Figure 4.3 Thalomid Market Forecast ($m), 2009-2021 Figure 5.1 Carfilzomib Market Forecast ($m), 2009-2021 Figure 5.2 Actimid Market Forecast ($m), 2009-2021 Figure 5.3 Panobinostat Market Forecast ($m), 2009-2021 Figure 5.4 Perifosine Market Forecast ($m), 2009-2021 Figure 5.5 Aplidin Market Forecast ($m), 2009-2021 Figure 5.6 Elotuzumab Market Forecast ($m), 2009-2021 Figure 5.7 Siltuximab Market Forecast ($m), 2009-2021 Figure 9.1 US: Market Forecast ($m), 2009-2021 Figure 9.2 Japan: Market Forecast ($m), 2009-2021 Figure 9.3 EU Top 5 Market Forecasts ($m), 2009-2021 Figure 9.4 Brazil: Market Forecast ($m), 2009-2021 Figure 9.5 Russia: Market Forecast ($m), 2009-2021 Figure 9.6 India: Market Forecast ($m), 2009-2021 Figure 9.7 China: Market Forecast ($m), 2009-2021 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
